Shenzhen Luwei Biotechnology (Biomanifold Technology) Co., Limited is committed to developing clinical applications of molecular diagnostics for cancer and other serious diseases in people of Chinese and other ancestries. Its technical team has more than 30 years of combined industry experience at successful U.S. in vitro diagnostics companies. Its operations team comes from the founder of a local publicly listed company and is pursuing a second entrepreneurial venture.

Luwei’s technology uses pioneering algorithmic models built on transcriptomic data. Its clinically actionable multigene diagnostic products address cancer recurrence, disease-free and overall survival, treatment response, early diagnosis and prognosis. They help physicians and patients make data-driven decisions about postoperative chemotherapy, treatment optimization, drug response and disease monitoring.

Biomanifold Technology is committed to providing in vitro diagnostic products and third-party clinical laboratory services for clinicians, patients and pharmaceutical companies, and to advancing precision medicine in China and worldwide.